Imatinib mesylate (STI571) for myeloid malignancies other than CML

被引：15
作者：
Krystal, GW
机构：
[1] Virginia Commonwealth Univ, Div Hematol Oncol, Richmond, VA 23249 USA
[2] McGuire Dept Vet Affairs Med Ctr, Richmond, VA 23249 USA
来源：
LEUKEMIA RESEARCH | 2004年 / 28卷
关键词：
imatinib mesylate; myeloid neoplasms; CML;
D O I：
10.1016/j.leukres.2003.10.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Imatinib mesylate, a small molecule tyrosine kinase inhibitor, has had a major impact on the treatment of Philadelphia chromosome positive chronic myelogenous leukemia. This review will explore its potential in the treatment of other myeloid neoplasms, based on its ability to inhibit Kit and PDGFR kinases in addition to Bcr-Abl. Imatinib's potential role in the treatment of Philadelphia chromosome negative chronic myelogenous leukemia, systemic mastocytosis with associated hematologic neoplasms, chronic myelomonocytic leukemia, specific subtypes of acute myelogenous leukemia, myelofibrosis/myeloid metaplasia, and polycythemia vera is discussed. Published by Elsevier Ltd.
引用
收藏
页码：S53 / S59
页数：7
相关论文
共 67 条
[1]   Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis [J].
Abu-Duhier, FM ;
Goodeve, AC ;
Care, RS ;
Gari, M ;
Wilson, GA ;
Peake, IR ;
Reilly, JT .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (03) :464-470
[2]  
Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299
[3]   Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].
Apperley, JF ;
Gardembas, M ;
Melo, JV ;
Russell-Jones, R ;
Bain, BJ ;
Baxter, J ;
Chase, A ;
Chessells, JM ;
Colombat, M ;
Dearden, CE ;
Dimitrijevic, S ;
Mahon, FX ;
Marin, D ;
Nikolova, Z ;
Olavarria, E ;
Silberman, S ;
Schultheis, B ;
Cross, NCP ;
Goldman, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487
[4]   Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL [J].
Azam, M ;
Latek, RR ;
Daley, GQ .
CELL, 2003, 112 (06) :831-843
[5]   C-kit mutations in core binding factor leukemias [J].
Beghini, A ;
Peterlongo, P ;
Ripamonti, CB ;
Larizza, L ;
Cairoli, R ;
Morra, E ;
Mecucci, C .
BLOOD, 2000, 95 (02) :726-727
[6]  
Beghini Alessandro, 2002, Hematol J, V3, P157, DOI 10.1038/sj.thj.6200168
[7]  
Buchdunger E, 1996, CANCER RES, V56, P100
[8]  
Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
[9]   Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis:: A possible explanation for divergent clinical behavior [J].
Büttner, C ;
Henz, BM ;
Welker, P ;
Sepp, NT ;
Grabbe, J .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 111 (06) :1227-1231
[10]   CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J].
Carroll, M ;
OhnoJones, S ;
Tamura, S ;
Buchdunger, E ;
Zimmermann, J ;
Lydon, NB ;
Gilliland, DG ;
Druker, BJ .
BLOOD, 1997, 90 (12) :4947-4952
1234567